|
|
萨城迎来首批疫苗实验参与者！
SACRAMENTO (CBS13) — Sitting at a doctor’s office or an urgent care room can be a little nerve-wracking sometimes, but today is different for Kelli Benedetti.
坐在医生的办公室或急症室有时会让人有点神经紧张，但今天对凯利·贝内代蒂来说就不一样了。
“In terms of getting a vaccine, no not nervous,” Benedetti, a vaccine trial participant, said.
“在接种疫苗方面，不要紧张，”疫苗试验参与者Benedetti说。
She’s one of the first eight participants to join the Moderna phase three COVID-19 vaccine trial happening at Benchmark Research in Sacramento.
她是首批参加在萨克拉门托基准研究中心(Benchmark Research)进行的新冠肺炎三期疫苗试验的八名参与者之一。
“Well, I wasn’t totally on board at first. But my husband is a doctor and he’s been seeing a lot of COVID patients lately,” Benedetti said. “And he said, ‘It’s inevitable I’ll bring it home so might as well contribute to research.”
“嗯，一开始我并不完全赞同。但我的丈夫是一名医生，最近他看了很多COVID患者。”“他说，‘我不可避免地会把它带回家，这样也可以用来做研究。’”
The researchers doing the study couldn’t be more excited to get finally get things started.
做这项研究的研究人员终于可以开始了。
“Huge day! Probably a day I’ll never forget; the day we started the trial. Hopefully, we can cross our fingers that it works,” Doctor Greg Hachigian, Principal Investigator for the Moderna Study, said.
“伟大的一天!也许是我永远不会忘记的一天;我们祈祷它起作用，”Moderna研究的首席研究员格雷格·哈奇吉安博士说。
“It’s been a couple of stressful weeks to try to get it organized and get it up and going. But we are certainly very excited,” Nav Kooner, Site Director for Benchmark Research – Sacramento, said.
“这是紧张的几个星期，试图让它运作。但我们当然非常兴奋，”萨克拉门托基准研究的现场主管Nav Kooner说。
The trial will test at least 300 or more people locally and 30,000 people nationwide with either a placebo or the potential COVID-19 vaccine. The research will kick into high-gear in the event someone does contract the virus.
该试验将对当地至少300人或更多人和全国3万人进行安慰剂或潜在的COVID-19疫苗测试。如果有人感染了病毒，研究将会进入高速状态。
“We want to see how bad their symptoms are, do they end up in the hospital or is it a very minor infection,” Doctor Greg Hachigian, Principal Investigator for Moderna Study, said. “And we’re going to compare that to the placebo group, see how they did with the COVID infection. That’s how we are going to know if this vaccine really works.”
“我们想看看他们的症状有多严重，他们最终会去医院吗，还是只是轻微的感染，”Moderna研究的首席研究员格雷格·哈奇吉安博士说。“我们将把这一组与安慰剂组进行比较，看看他们对待COVID感染的情况。这样我们才能知道这种疫苗是否真的有效。”
A long road filled with plenty of research and willingness of others to stop the spread.
这是一条充满了大量研究和其他人阻止传播的意愿的漫长道路。
“I’m very, very proud of anyone who comes in,” Hachigian said. “They’re heroes. The people coming in today are heroes.”
哈奇吉安说:“我对前来的人感到非常、非常自豪。”“他们是英雄。今天来的人都是英雄。”
“I don’t see myself as like a hero or anything. But, I think that anything for science and to push knowledge forward – obviously my occupation is a scientist so that’s what I am all about – and I definitely think that this is important,” Benedetti said.
“我不认为自己是英雄或什么的。但是，我认为任何为了科学和推动知识发展的事情——显然我的职业是科学家，所以这就是我的全部——我肯定认为这是重要的。”
The principal investigator for the study says this trial is beneficial in two ways. He told CBS13 the vaccine isn’t made from the COVID-19 pathogen so you can’t get the virus by being injected with this potential vaccine.
这项研究的主要研究者说，这项试验在两个方面是有益的。他告诉CBS13，这种疫苗不是由COVID-19病原体制成的，所以你不会通过注射这种潜在的疫苗而感染病毒。
Secondly, Hachigian said since it’s being created in a lab the vaccine can be produced much quicker than a vaccine made from an egg protein.
其次，Hachigian说，由于这种疫苗是在实验室中制造出来的，所以它的生产速度比用蛋白制造的疫苗要快得多。
The lab is confident it will recruit the 300-plus participants for the study. If you’re interested in taking part in the study, you can call 1-888-902-9605 for more information.
该实验室有信心招募300多名参与者参与这项研究。如果您有兴趣参加这项研究，您可以拨打1-888-902-9605获取更多信息。
联系人:-
电话号码: |
|
发表于 2020-7-28 09:50:55
发表于 2022-12-27 04:53:19